BRCA1/2 germline mutations and response to PARP inhibitor treatment in lung cancer.

e13007Background: Germline mutations in BRCA1/2 (BReast CAncer genes 1 and 2), which are targets for PARP inhibitors in breast and ovarian cancer, have been previously identified in patients with n...